PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0
PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Submission of Matters to a Vote of Security Holders

PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Protagenic Therapeutics, Inc. (the “Company”) held its 2019 Annual Meeting of Stockholders (the “Annual Meeting”) on September 23, 2019. Holders of an aggregate of 10,261,419 shares of the Company’s Common Stock at the close of business on July 30, 2019 were entitled to vote at the Annual Meeting, of which 5,544,957 shares were present in person or represented by proxy. At the Annual Meeting, the Company’s stockholders voted as follows:

Proposal One: The stockholders elected each of the following individuals as a director for a one year term expiring on the date of the Company’s 2020 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.


About PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX)

Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.